-
Clinical Value Creator
-
Dedicate to defeating major diseases, enhance the quality of life
-
Focus on investment value, co-create and share a win-win future
About Us
RemeGen is committed to the discovery, development, production and commercialization of first-in-class and best-in-class biological drugs, and has developed a series of innovative biologics with significant clinical value for major diseases such as autoimmunity, oncology, and ophthalmology.
RemeGen Co., Ltd. (Yantai) was co-founded in 2008 by Mr. Wang Weidong, founder of Rongchang Pharmaceuticals, and Dr. Jianmin Fang a Canadian-American scientist. RemeGen is headquartered in Yantai, Shandong Province, China, with R&D centers and offices in China and the United States.
Learn More
-
2A+H Dual-listed
-
8Clinical Pipelines
-
40 +Clinical Trials
-
600 +Patent Applications
Product Pipeline
Learn More
Telitacicept
The World’s First Innovative Dual-target Biological Drug to Treat Systemic Lupus Erythematosus The World’s First Innovative Dual-target Biological Drug to Treat Systemic Lupus Erythematosus Trade name: Tai’ai ® Synonym: RC18 Target: BLyS and APRIL Learn More
Disitamab Vedotin
China’s First Independently Developed Innovative ADC China’s First Independently Developed Innovative ADC Trade name: Aidixi® Synonym: RC48 Target: HER2 Learn More
Top News Express
Learn More
-
2026 ASCO-GU | RC48-C017 study update: Disitamab vedotin plus immunotherapy as neoadjuvant treatment delivers lasting survival gains in bladder cancer.
2026-02-28
On February 27 local time, at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU) held in San Francisco, USA, the latest efficacy and safety data from the extended follow-up of the phase II clinical study (RC48-C017) o
-
2026 JPM | Rongchang Biotech: Delivering Innovation at Scale, Solidifying Its Global Competitive Edge for the Future
2026-01-16
On January 15 at 9:00 a.m. local time, Dr. Jianmin Fang, CEO of RemeGen, took the stage at the 44th J.P. Morgan Healthcare Conference in San Francisco—a premier global event for pharmaceutical innovation and investment trends. In his keynote address
-
ESMO Congress 2025 Presidential Symposium Oral Presentation | Disitamab Vedotin Achieves Major Breakthrough as First-Line Treatment for Urothelial Carcinoma
2025-10-20
BERLIN, Oct. 20, 2025 /PRNewswire/ -- At the 2025 European Society for Medical Oncology (ESMO) Congress, a Phase III clinical study on disitamab vedotin plus toripalimab versus chemotherapy as first-line treatment for HER2-expressing locally adv
-
Results of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual Meeting
2025-09-17
YANTAI, China, Sept. 17, 2025 /PRNewswire/ -- RemeGen (688331.SH/09995.HK) announced that the 48-week open-label extension (OLE) data from China Phase III clinical study of telitacicept (RC18, brand name: 泰爱®, a BLyS/APRIL dual-targ
-
RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries
2025-08-18
YANTAI, China, Aug. 18, 2025 /PRNewswire/ -- RemeGen Co., Ltd. (Stock Code: 688331.SH/09995.HK, "RemeGen"), a leading Chinese biopharmaceutical company, announced today that it has entered into an agreement with Santen Pharmaceuti
-
Telitacicept Meets Primary Endpoint in Phase III Trial for Primary Sjögren's Syndrome in China
2025-08-13
YANTAI, China, Aug. 13, 2025 /PRNewswire/ -- On August 13th, Remegen (688331.SH/09995.HK) announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, Telitacicept, met the primary endpoint in its Phase I
-
2026-02-28
2026 ASCO-GU | RC48-C017 study update: Disitamab vedotin plus immunotherapy as neoadjuvant treatment delivers lasting survival gains in bladder cancer./p>
-
2026-01-16
2026 JPM | Rongchang Biotech: Delivering Innovation at Scale, Solidifying Its Global Competitive Edge for the Future /p>
-
2025-10-20
ESMO Congress 2025 Presidential Symposium Oral Presentation | Disitamab Vedotin Achieves Major Breakthrough as First-Line Treatment for Urothelial Carcinoma/p>
Investor Services
Learn More
Financial Reports
Corporate Governance
Circulars
STAR Market stock code
荣昌生物：688331.SH
HKEX stock code
荣昌生物：09995.HK
Embrace Outstanding Talents
Learn More
Embracing a “people first” talent concept, we have established a mature employee career development system, providing diverse learning and training programs, offering competitive compensation and benefits, and creating a broad platform for the development of various talents.
No. 58 Beijing Middle Road, Yantai Development Zone, Shandong, China.
（+86）535-3573511
Official WeChat